Cannabis News

Medicinal Cannabis: Dr Luisa discusses the benefits for mental health conditions


strelov/iStock via Getty Images

The lower house of the US Congress has approved a key bill to legalize marijuana at the federal level.

After an hour of debate on Friday, the full chamber voted 220 to 204 to approve the MORE Act, marking the second time the bill has passed the House. Three Republicans supported the measure and two Democrats opposed it.

The Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, sponsored by House Judiciary Committee Chairman Jerrold Nadler (D-NY), seeks to remove cannabis from the list of federally controlled substances, among other things Goals.

An earlier version of the MORE Act cleaned the house floor in December 2020, but it stalled in the Senate.

News of the upcoming vote on the bill propelled cannabis stocks rose at the end of last week.

Canadian Licensed Producers: Canopy Growth (NASDAQ:GCC +0.8%), Tilray (NASDAQ:TLRY +2.3%), Chronos (NASDAQ:CRON +1.5%), Aurora Cannabis (NASDAQ:ACB +1.5%), producers of sundials (SNDL +4.2%), OrganiGram Holdings (OGI +3.0%), HEXO Corp (HEXO +0.8%)

US MSOs: MedMen Enterprises (OTCQB:MMNFF +3.9%), Curaleaf Holdings (OTCPK: CURVE -0.7%), Area holdings (OTCQX: ACRHF +4.8%), Harvest Health & Leisure (OTCQX: HRVSF), Cresco Labs (OTCQX: CRLBF +3.1%), Green Thumb Industries (OTCQX: GTBIF +1.1%), Trulieve Cannabis (OTCQX:TCNNF -0.5%), Ayr Wellness (OTCQX: AYRWF +0.1%), Columbia Care (OTCQX: CCHWF +2.0%), TerrAscend (OTCQX: TRSSF +4.2%)

As lawmakers were expected to consider the bill,…

Original author link click here to read the full story.

strelov/iStock via Getty Images

The lower house of the US Congress has approved a key bill to legalize marijuana at the federal level.

After an hour of debate on Friday, the full chamber voted 220 to 204 to approve the MORE Act, marking the second time the bill has passed the House. Three Republicans supported the measure and two Democrats opposed it.

The Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, sponsored by House Judiciary Committee Chairman Jerrold Nadler (D-NY), seeks to remove cannabis from the list of federally controlled substances, among other things Goals.

An earlier version of the MORE Act cleaned the house floor in December 2020, but it stalled in the Senate.

News of the upcoming vote on the bill propelled cannabis stocks rose at the end of last week.

Canadian Licensed Producers: Canopy Growth (NASDAQ:GCC +0.8%), Tilray (NASDAQ:TLRY +2.3%), Chronos (NASDAQ:CRON +1.5%), Aurora Cannabis (NASDAQ:ACB +1.5%), producers of sundials (SNDL +4.2%), OrganiGram Holdings (OGI +3.0%), HEXO Corp (HEXO +0.8%)

US MSOs: MedMen Enterprises (OTCQB:MMNFF +3.9%), Curaleaf Holdings (OTCPK: CURVE -0.7%), Area holdings (OTCQX: ACRHF +4.8%), Harvest Health & Leisure (OTCQX: HRVSF), Cresco Labs (OTCQX: CRLBF +3.1%), Green Thumb Industries (OTCQX: GTBIF +1.1%), Trulieve Cannabis (OTCQX:TCNNF -0.5%), Ayr Wellness (OTCQX: AYRWF +0.1%), Columbia Care (OTCQX: CCHWF +2.0%), TerrAscend (OTCQX: TRSSF +4.2%)

As lawmakers were expected to consider the bill,…

source link





#Medicinal #Cannabis #Luisa #discusses #benefits #mental #health #conditions

Related Posts

Leave a Reply